Sarcomas are uncommon malignancies which gather more than 80 different subtypes in the most recent WHO
classification. Surgery remains the mainstay for the treatment of localized disease; however, effective treatment of advanced
soft tissue sarcoma remains a challenge. Advances in understanding the molecular biology and carcinogenesis of
sarcoma have allowed for rapid development of new targeted therapies. In this review we will provide current knowledge
on antiangiogenic therapies in non-GIST soft tissue sarcomas. The contribution of angiogenesis to sarcoma development
has been documented in preclinical models, and in the clinic. Angiogenesis plays a central role in the growth and dissemination
of soft tissue sarcoma and correlates with higher-grade STS and a poorer outcome. Many angiogenesis inhibitors
have shown activity in STS and pazopanib an antiangiogenic agent is now available in clinical routine. In this manuscript,
we will present the results of preclinical research and clinical trials that have evaluated angiogenesis inhibitors in non
GIST soft tissue sarcomas.
Keywords: Angiogenesis, angiogenesis inhibitors, soft tissue sarcomas, targeted therapy, vascular endothelial growth factor.
Rights & PermissionsPrintExport